m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04220)
Name
[131I]-BC8
Status
Phase 2
TTD Drug ID
D0G5OE
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Leukocyte common antigen (PTPRC)
Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Leukocyte common antigen (PTPRC) is a therapeutic target for [131I]-BC8. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of [131I]-BC8 through regulating the expression of Leukocyte common antigen (PTPRC). [1], [2]
Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Leukocyte common antigen (PTPRC) is a therapeutic target for [131I]-BC8. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of [131I]-BC8 through regulating the expression of Leukocyte common antigen (PTPRC). [1], [2]
References
Ref 1 Roles of the m(6)A Modification of RNA in the Glioblastoma Microenvironment as Revealed by Single-Cell Analyses. Front Immunol. 2022 Apr 26;13:798583. doi: 10.3389/fimmu.2022.798583. eCollection 2022.
Ref 2 Clinical pipeline report, company report or official report of Actinium Pharmaceuticals.